Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Oral Treprostinil and Ethanol
NCT02318758Phase 1Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Sep 2014
- Primary completion
- Oct 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of treprostinil in pulmonary arterial hypertension (PAH) (4 arms), sponsored by United Therapeutics Corporation. Primary endpoint: Maximum Plasma Concentration at 24 days. Started Sep 2014; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02318758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02318758.